You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients

Citation Tools

Article menu

Download PDFPDF

Palliative care
388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Peen U, Graybill W, González-Martin A, et al
388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients
International Journal of Gynecologic Cancer 2020;30:A90-A91.